Substance Use Tools & Resources    

This module introduces family support professionals and other service providers to basic information about the importance of medication compliance, and provides an understanding of how pregnant and parenting women being treated for behavioral health or medical conditions may be non-compliant or misuse medications. It prepares service providers to recognize women who may be at risk for noncompliance or misuse of medications, develop a plan for referral, and support women with behavioral health problems or medical condition.

The Council on Patient Safety in Women’s Health Care disseminates patient safety bundles to help facilitate the standardization process. This bundle reflects emerging clinical, scientific, and patient safety advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Although the components of a particular bundle may be adapted to local resources, standardization within an institution is strongly encouraged.

This toolkit provides tools to both providers and patients for the assessment and management of perinatal mood and anxiety disorders, as well as substance use disorders (SUD).

This NIDA policy brief shares evidence-based research on treating opioud use dissorder on pregnancy, including the assessment of methadone and buprenorphine as treatment.

This program — Support for Hospital Opioid Use Treatment (Project SHOUT) — provides clinical leaders with the tools they need to start and maintain patients on buprenorphine or methadone during hospitalizations for any condition, be it medical, surgical, or obstetric.

Guides States, Tribes, and local communities on best practices for collaborative treatment approaches for women with SUDs. Highlights data on the effects of opioids on pregnant women and the risks and benefits associated with MAT.

Provides information for pregnant women about how taking methadone or buprenorphine may affect delivery, breastfeeding, and newborn infants.

These guidelines contain recommendations on the identification and management of substance use and substance use disorders for health care services which assist women who are pregnant, or have recently had a child, and who use alcohol or drugs or who have a substance use disorder.

Gives clinicians information about treating pregnant women with buprenorphine.

The PRO screens pregnant women for psychosocial risk factors that may affect a healthy pregnancy or birth or impede a woman’s ability to comply with prenatal care recommendations.